利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

7 条记录 (耗时 0.026 秒)

    Solid state forms of racemic ilaprazole
    1.
    发明授权
    Solid state forms of racemic ilaprazole 有权
    外消旋伊拉唑的固体形式

    公开(公告)号：US07999110B2

    公开(公告)日：2011-08-16

    申请号：US11966868

    申请日：2007-12-28

    申请人： John M. Brackett ,  David T. Jonaitis ,  Wei Lai ,  Jih Hua Liu ,  Stephan D. Parent ,  Jinyu Shen

    发明人： John M. Brackett ,  David T. Jonaitis ,  Wei Lai ,  Jih Hua Liu ,  Stephan D. Parent ,  Jinyu Shen

    IPC分类号： C07D401/14

    CPC分类号： C07D401/14

    摘要： The invention relates to crystalline forms of racemic ilaprazole, 2[[(4-methoxy-3-methyl-2 -pyridinyl)-methyl]sulfinyl]-5-(1 H-pyrrol-1-yl) 1H-Benzimidazole. The invention also relates to a pharmaceutical composition for inhibiting gastric acid secretion comprising a crystalline Form of ilaprazole according to the invention in an amount effective to inhibit gastric acid secretion and a pharmaceutically acceptable carrier. The invention also provides methods of treatment for various acid-related gastrointestinal (GI) disorders.

    摘要翻译： 本发明涉及外消旋伊拉唑，2 [[（4-甲氧基-3-甲基-2-吡啶基） - 甲基]亚磺酰基] -5-（1H-吡咯-1-基）1H-苯并咪唑的结晶形式。 本发明还涉及用于抑制胃酸分泌的药物组合物，其包含有效抑制胃酸分泌的量的本发明的伊拉唑结晶形式和药学上可接受的载体。 本发明还提供了治疗各种酸相关胃肠道（GI）障碍的方法。

    Solid state forms of racemic ilaprazole
    2.
    发明授权
    Solid state forms of racemic ilaprazole 有权
    外消旋伊拉唑的固体形式

    公开(公告)号：US08592600B2

    公开(公告)日：2013-11-26

    申请号：US12939276

    申请日：2010-11-04

    申请人： John M. Brackett ,  David T. Jonaitis ,  Wei Lai ,  Jih Hua Liu ,  Stephan D. Parent ,  Jinyu Shen

    发明人： John M. Brackett ,  David T. Jonaitis ,  Wei Lai ,  Jih Hua Liu ,  Stephan D. Parent ,  Jinyu Shen

    IPC分类号： C07D401/12

    CPC分类号： C07D401/14

    摘要： The invention relates to crystalline forms of racemic ilaprazole, 2[[(4-methoxy-3-methyl-2-pyridinyl)-methyl]sulfinyl]-5-(1H-pyrrol-1-yl) 1H-Benzimidazole. The invention also relates to a pharmaceutical composition for inhibiting gastric acid secretion comprising a crystalline Form of ilaprazole according to the invention in an amount effective to inhibit gastric acid secretion and a pharmaceutically acceptable carrier. The invention also provides methods of treatment for various acid-related gastrointestinal (GI) disorders.

    摘要翻译： 本发明涉及外消旋的伊拉唑，2 [[（4-甲氧基-3-甲基-2-吡啶基） - 甲基]亚磺酰基] -5-（1H-吡咯-1-基）1H-苯并咪唑的结晶形式。 本发明还涉及用于抑制胃酸分泌的药物组合物，其包含有效抑制胃酸分泌的量的本发明的伊拉唑结晶形式和药学上可接受的载体。 本发明还提供了治疗各种酸相关胃肠道（GI）障碍的方法。

    Solid state forms of racemic ilaprazole
    3.
    发明授权
    Solid state forms of racemic ilaprazole 有权
    外消旋伊拉唑的固体形式

    公开(公告)号：US08592599B2

    公开(公告)日：2013-11-26

    申请号：US12939266

    申请日：2010-11-04

    申请人： John M. Brackett ,  David T. Jonaitis ,  Wei Lai ,  Jih Hua Liu ,  Stephan D. Parent ,  Jinyu Shen

    发明人： John M. Brackett ,  David T. Jonaitis ,  Wei Lai ,  Jih Hua Liu ,  Stephan D. Parent ,  Jinyu Shen

    IPC分类号： C07D401/12

    CPC分类号： C07D401/14

    摘要： The invention relates to crystalline forms of racemic ilaprazole, 2[[(4-methoxy-3-methyl-2-pyridinyl)-methyl]sulfinyl]-5-(1H-pyrrol-1-yl)1H-Benzimidazole. The invention also relates to a pharmaceutical composition for inhibiting gastric acid secretion comprising a crystalline Form of ilaprazole according to the invention in an amount effective to inhibit gastric acid secretion and a pharmaceutically acceptable carrier. The invention also provides methods of treatment for various acid-related gastrointestinal (GI) disorders.

    摘要翻译： 本发明涉及外消旋的伊拉唑，2 [[（4-甲氧基-3-甲基-2-吡啶基） - 甲基]亚磺酰基] -5-（1H-吡咯-1-基）1H-苯并咪唑的结晶形式。 本发明还涉及用于抑制胃酸分泌的药物组合物，其包含有效抑制胃酸分泌的量的本发明的伊拉唑结晶形式和药学上可接受的载体。 本发明还提供了治疗各种酸相关胃肠道（GI）障碍的方法。

    Crystalline forms of solvated ilaprazole
    4.
    发明授权
    Crystalline forms of solvated ilaprazole 失效
    溶剂化伊拉唑的结晶形式

    公开(公告)号：US07989632B2

    公开(公告)日：2011-08-02

    申请号：US11966896

    申请日：2007-12-28

    申请人： John M. Brackett ,  David T. Jonaitis ,  Wei Lai ,  Jih Hua Liu ,  Stephan D. Parent

    发明人： John M. Brackett ,  David T. Jonaitis ,  Wei Lai ,  Jih Hua Liu ,  Stephan D. Parent

    IPC分类号： C07D401/12

    CPC分类号： C07D401/14

    摘要： The invention relates to crystalline forms of various solvates of ilaprazole, 2[[(4-methoxy-3-methyl-2-pyridinyl)-methyl]sulfinyl]-5-(1H-pyrrol-1-yl)1H-Benzimidazole. The invention also relates to a pharmaceutical composition for inhibiting gastric acid secretion comprising crystalline ilaprazole hydrate according to the invention in an amount effective to inhibit gastric acid secretion and a pharmaceutically acceptable carrier. The invention also provides methods of treatment for various acid-related gastrointestinal (GI) disorders.

    摘要翻译： 本发明涉及伊拉帕唑，2 [[（4-甲氧基-3-甲基-2-吡啶基） - 甲基]亚磺酰基] -5-（1H-吡咯-1-基）1H-苯并咪唑的各种溶剂合物的结晶形式。 本发明还涉及用于抑制胃酸分泌的药物组合物，其包含有效抑制胃酸分泌的量的本发明的结晶伊拉拉唑水合物和药学上可接受的载体。 本发明还提供了治疗各种酸相关胃肠道（GI）障碍的方法。

    Bioreagent immobilization medium
    5.
    发明授权
    Bioreagent immobilization medium 失效
    生物固定培养基

    公开(公告)号：US5643721A

    公开(公告)日：1997-07-01

    申请号：US193972

    申请日：1994-02-09

    申请人： Thomas G. Spring ,  John M. Brackett ,  Sheila A. Vogdes ,  Steven G. Schultz

    发明人： Thomas G. Spring ,  John M. Brackett ,  Sheila A. Vogdes ,  Steven G. Schultz

    IPC分类号： C12N11/14 ,  C12Q1/25 ,  G01N27/06 ,  G01N33/543 ,  G01N33/545 ,  G01N33/548 ,  G01N33/551

    CPC分类号： G01N33/545 ,  G01N33/543 ,  G01N33/5436 ,  Y10S435/817 ,  Y10S436/806

    摘要： The present invention provides an immobilization medium which can immobilize bioreagents to support materials and which dries to a water resistant layer or film. The immobilization medium comprises (i) a liquid or fluid binding reagent and (ii) complexes of a bioreagent immobilized to a solid phase which are evenly dispersed within the binding reagent. The suspension can further include supplemental ingredients evenly dispersed throughout the medium which can provide the medium with electrochemical properties, enhance the stability of the immobilized bioreagent and/or improve the medium's capability of drying to a substantially water resistant or insoluble layer. The immobilization medium provided by the instant invention is in the form of a homogeneous liquid suspension.

    摘要翻译： 本发明提供一种固定培养基，其可以将生物试剂固定在支撑材料上并干燥到防水层或膜上。 固定培养基包括（i）液体或流体结合试剂和（ii）固定在固相上的生物试剂的复合物，其均匀分散在结合试剂中。 悬浮液可以进一步包括均匀分散在整个培养基中的补充成分，其可以为培养基提供电化学性质，增强固定化生物试剂的稳定性和/或提高培养基对基本上防水或不溶性层的干燥能力。 由本发明提供的固定介质是均匀的液体悬浮液的形式。

    Lead detection method and reggents utilizing aminolevulinic acid dehydratase and tertiary phosphines
    7.
    发明授权
    Lead detection method and reggents utilizing aminolevulinic acid dehydratase and tertiary phosphines 失效
    铅检测方法和利用氨基乙酰丙酸脱水酶和叔膦的方法

    公开(公告)号：US5552297A

    公开(公告)日：1996-09-03

    申请号：US419845

    申请日：1995-04-11

    申请人： Martin Wong ,  John M. Ramp ,  John M. Brackett

    发明人： Martin Wong ,  John M. Ramp ,  John M. Brackett

    IPC分类号： G01N33/52 ,  G01N33/84 ,  C12Q1/32 ,  G01N33/53

    CPC分类号： G01N33/84 ,  G01N33/52 ,  Y10S435/81

    摘要： A method and kit for simplifying and improving the sensitivity and accuracy of a lead assay for a sample solution suspected of containing lead determines the extent of a reaction between a substrate and a disulfide enzyme in the presence of an activating reagent which contains a water-soluble tertiary phosphine reagent so as to increase the activity of the disulfide enzyme for reaction with the substrate. For a colorimetric determination of the enzyme activity a chromophore is formed upon reaction with a selected component of the sample solution in the presence of a colorimetric enhancing reagent. The colorimetric enhancing reagent contains a metal ion such as cupric ion or ferric ion which is soluble in the sample solution. The extent of the chromophore formation is then photometrically determined.

    摘要翻译： 用于简化和提高疑似含有铅的样品溶液的铅测定的灵敏度和准确度的方法和试剂盒确定了在含有水溶性的活化试剂存在下底物和二硫化物酶之间的反应程度 以提高二硫化物酶与底物反应的活性。 为了比色测定酶活性，在比色增强剂的存在下，与样品溶液的选定组分反应形成发色团。 比色增强剂含有可溶于样品溶液的金属离子如铜离子或铁离子。 然后光度测定发色团形成的程度。